Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹766 Cr
Revenue (TTM)
₹620 Cr
Net Profit (TTM)
₹38 Cr
ROE
18.6 %
ROCE
21.9 %
P/E Ratio
26.4
P/B Ratio
2.9
Industry P/E
34.62
EV/EBITDA
15.4
Div. Yield
0.1 %
Debt to Equity
0.1
Book Value
₹217.2
EPS
₹24.7
Face value
10
Shares outstanding
11,784,000
CFO
₹22.82 Cr
EBITDA
₹90.49 Cr
Net Profit
₹76.47 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
REMUS
| -13.6 | -14.0 | -17.2 | -41.9 | -- | -- | -- |
|
BSE Healthcare
| -4.8 | -4.1 | -6.6 | -1.9 | 24.1 | 14.8 | 10.3 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
REMUS
| -43.5 | 33.7 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Healthcare
| -3.3 | 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
REMUS
|
606.8 | 766.3 | 620.4 | 38.4 | -- | 18.6 | 26.4 | 2.9 |
| 2,268.2 | 18,638.4 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.9 | 12.3 | |
| 646.6 | 12,769.7 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.3 | 2.3 | |
| 580.2 | 14,362.3 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.3 | 3.5 | |
| 816.2 | 12,973.5 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30 | 2.0 | |
| 927.6 | 16,639.3 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 10.7 | 1.9 | |
| 1,389.1 | 15,840.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 788 | 2.7 | |
| 133.3 | 17,758.8 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.2 | |
| 397.9 | 16,010.8 | 3,720.2 | 352.1 | 13.7 | 8.2 | 45.5 | 3.4 | |
| 1,100.3 | 17,911.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 814.2 | 3.9 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
2015
Chairman
Swapnil Jatinbhai Shah
Managing Director
Arpit Deepakkumar Shah
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Remus Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Remus Pharmaceuticals Ltd is ₹606.80 (NSE) as of 23-Mar-2026 15:46 IST. Remus Pharmaceuticals Ltd has given a return of -41.86% in the last 1 years.
The P/E ratio of Remus Pharmaceuticals Ltd is 26.36 times as on 20-Mar-2026, a 24 discount to its peers’ median range of 34.62 times.
The P/B ratio of Remus Pharmaceuticals Ltd is 2.93 times as on 20-Mar-2026, a 3 discount to its peers’ median range of 3.03 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.68
|
5.15
|
|
2024
|
6.18
|
6.43
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Remus Pharmaceuticals Ltd are Rs 1,145.00 and Rs 580.00 as of 23-Mar-2026.
Remus Pharmaceuticals Ltd has a market capitalisation of ₹ 766 Cr as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Remus Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-43.50
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.